Minggui Pan, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 20
- 4 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
20 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pan’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
20 of 20 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A64776 · Current
Licensed to practise in California · since 1998 · expires 2028-04-30 · Fujian Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$81,729
Medicare paid this office $81,729 for 184 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 78 | $34,408 | $165 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $20,350 | $106 |
| Long return visit (40+ min) | 25 | $7,552 | $128 |
| New patient visit (60+ min) | 30 | $5,958 | $199 |
| Hospital discharge day management, more than 30 minutes | 34 | $3,650 | $101 |
See all 8 services
| Long return visit (40+ min) | 78 | $34,408 | $165 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $20,350 | $106 |
| Long return visit (40+ min) | 25 | $7,552 | $128 |
| New patient visit (60+ min) | 30 | $5,958 | $199 |
| Hospital discharge day management, more than 30 minutes | 34 | $3,650 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $2,945 | $155 |
| New patient visit (60+ min) | 13 | $2,115 | $163 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,738 | $116 |
Who their Medicare patients are
184 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 11% · Women 50% · Also on Medicaid 30% · Health risk score 2.39. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 75% · Cancer 51% · Diabetes 34% · Chronic kidney disease 32% · Coronary heart disease 31% · Depression 28% · Atrial fibrillation 26% · Heart failure 21% · COPD 18% · Dementia 15% · Stroke 10%.
The office billed $373,626, Medicare allowed $105,246 and paid $81,729; for 607 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 184 | 607 | 73 | 2.39 | $373,626 | $81,729 |
| 2023 | 65 | 187 | 73 | 1.63 | $93,947 | $21,454 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 23 | $5,328 | $130 |
| New patient visit (60+ min) | 30 | $4,895 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,210 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,037 | $107 |
Medicaid work
$6,234 in 2024
Medicaid paid $6,234 for 132 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 78 | $4,713 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 54 | $1,521 |
| 2024 | 132 | 2 | 16 | $6,234 |
Drugs they prescribed that Part D paid
$586,072
Pharmacies billed $586,072 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 9% of their Part D prescriptions (21 of 229) in 2024. Above the middle of the specialty; the typical medical oncology clinician is at 6%.
172 generic and 57 brand-name prescriptions · $586,072 in drug cost · 17 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Zarxio | 16 | $55,286 | $3,455 |
| Eliquis | 20 | $11,002 | $550 |
| Imatinib Mesylate | 12 | $554 | $46 |
| Klor-Con | 12 | $533 | $44 |
| Oxycodone | 12 | $175 | $15 |
See all 7 drugs
| Zarxio | 16 | $55,286 | $3,455 |
| Eliquis | 20 | $11,002 | $550 |
| Imatinib Mesylate | 12 | $554 | $46 |
| Klor-Con | 12 | $533 | $44 |
| Oxycodone | 12 | $175 | $15 |
| Ondansetron | 13 | $88 | $7 |
| Prednisone | 11 | $70 | $6 |
Year by year
| 2024 | 229 | 41 | 9% (21) | 25% | $586,072 |
| 2023 | 396 | 111 | 4% (15) | None | $769,809 |
| 2022 | 1,263 | 157 | 5% (63) | 28% | $3,978,074 |
| 2021 | 1,101 | 135 | 9% (98) | None | $3,781,646 |
| 2020 | 1,099 | 145 | 5% (53) | None | $3,419,637 |
| 2019 | 1,030 | 165 | 8% (85) | None | $2,652,745 |
| 2018 | 825 | 154 | 10% (85) | 31% | $2,376,466 |
| 2017 | 661 | 146 | 4% (27) | 25% | $1,444,933 |
| 2016 | 804 | 190 | 9% (71) | 32% | $1,293,403 |
| 2015 | 873 | 191 | 12% (102) | 24% | $793,204 |
| 2014 | 1,005 | 202 | 14% (141) | None | $979,899 |
| 2013 | 807 | 187 | 11% (86) | None | $972,103 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Tagrisso | 18 | $272,229 | $15,124 |
| Ibrance | 19 | $224,212 | $11,801 |
| Xtandi | 12 | $128,824 | $10,735 |
| Abiraterone Acetate | 60 | $19,312 | $322 |
| Exemestane | 13 | $1,265 | $97 |
| Imatinib Mesylate | 21 | $992 | $47 |
| Anastrozole | 38 | $949 | $25 |
| Prednisone | 48 | $413 | $9 |
| Ondansetron | 16 | $116 | $7 |
2022: 28 drugs
| Ibrance | 127 | $1,467,665 | $11,556 |
| Tagrisso | 54 | $844,132 | $15,632 |
| Xtandi | 60 | $607,859 | $10,131 |
| Lenvima | 14 | $256,126 | $18,295 |
| Iressa | 20 | $154,015 | $7,701 |
| Everolimus | 25 | $70,766 | $2,831 |
| Abiraterone Acetate | 220 | $50,644 | $230 |
| Enoxaparin | 16 | $4,085 | $255 |
| Imatinib Mesylate | 48 | $2,965 | $62 |
| Anastrozole | 66 | $1,607 | $24 |
| Prednisone | 167 | $1,585 | $9 |
| Exemestane | 13 | $1,508 | $116 |
| Megestrol Acetate | 17 | $1,008 | $59 |
| Potassium Chloride | 14 | $635 | $45 |
| Nystatin | 25 | $612 | $24 |
| Hydrocodone-Acetaminophen | 15 | $547 | $36 |
| Bicalutamide | 14 | $464 | $33 |
| Levothyroxine | 16 | $424 | $27 |
| Morphine Sulfate Er | 16 | $336 | $21 |
| Ondansetron | 32 | $335 | $10 |
| Oxycodone-Acetaminophen | 15 | $296 | $20 |
| Dexamethasone | 11 | $285 | $26 |
| Diphenoxylate-Atropine | 13 | $215 | $17 |
| Prochlorperazine Maleate | 11 | $184 | $17 |
| Propranolol | 12 | $164 | $14 |
| Amlodipine Besylate | 12 | $149 | $12 |
| Lorazepam | 16 | $134 | $8 |
| Famotidine | 11 | $101 | $9 |
2021: 21 drugs
| Ibrance | 133 | $1,379,854 | $10,375 |
| Lenvima | 24 | $625,040 | $26,043 |
| Tagrisso | 40 | $597,460 | $14,937 |
| Xtandi | 25 | $262,351 | $10,494 |
| Everolimus | 34 | $238,507 | $7,015 |
| Votrient | 17 | $148,754 | $8,750 |
| Abiraterone Acetate | 178 | $32,873 | $185 |
| Imatinib Mesylate | 50 | $8,729 | $175 |
| Enoxaparin | 11 | $2,876 | $261 |
| Prednisone | 140 | $2,563 | $18 |
| Anastrozole | 62 | $1,531 | $25 |
| Hydrocodone-Acetaminophen | 34 | $964 | $28 |
| Levothyroxine | 19 | $550 | $29 |
| K-Tab Er | 15 | $527 | $35 |
| Oxycodone-Acetaminophen | 31 | $490 | $16 |
| Dexamethasone | 11 | $450 | $41 |
| Morphine Sulfate Er | 21 | $380 | $18 |
| Bicalutamide | 16 | $377 | $24 |
| Ondansetron | 29 | $326 | $11 |
| Famotidine | 16 | $137 | $9 |
| Lorazepam | 15 | $103 | $7 |
2020: 25 drugs
| Ibrance | 104 | $1,189,745 | $11,440 |
| Tagrisso | 39 | $581,083 | $14,900 |
| Xtandi | 29 | $295,551 | $10,191 |
| Votrient | 28 | $291,103 | $10,397 |
| Everolimus | 21 | $268,582 | $12,790 |
| Lenvima | 12 | $229,913 | $19,159 |
| Rubraca | 11 | $96,580 | $8,780 |
| Iressa | 11 | $89,395 | $8,127 |
| Abiraterone Acetate | 142 | $45,088 | $318 |
| Imatinib Mesylate | 82 | $11,757 | $143 |
| Anastrozole | 93 | $2,281 | $25 |
| Prednisone | 122 | $2,236 | $18 |
| Levothyroxine | 38 | $1,205 | $32 |
| Dexamethasone | 14 | $542 | $39 |
| Hydrocodone-Acetaminophen | 14 | $528 | $38 |
| Megestrol Acetate | 12 | $483 | $40 |
| Gabapentin | 18 | $467 | $26 |
| Ondansetron | 36 | $386 | $11 |
| Letrozole | 15 | $365 | $24 |
| Bicalutamide | 13 | $295 | $23 |
| K-Tab Er | 13 | $270 | $21 |
| Morphine Sulfate Er | 16 | $263 | $16 |
| Lorazepam | 27 | $222 | $8 |
| Oxycodone-Acetaminophen | 13 | $191 | $15 |
| Famotidine | 14 | $110 | $8 |
2019: 23 drugs
| Ibrance | 86 | $1,097,509 | $12,762 |
| Tagrisso | 26 | $360,409 | $13,862 |
| Afinitor | 16 | $250,021 | $15,626 |
| Xtandi | 22 | $205,015 | $9,319 |
| Cabometyx | 12 | $185,359 | $15,447 |
| Abiraterone Acetate | 92 | $141,466 | $1,538 |
| Imatinib Mesylate | 66 | $11,010 | $167 |
| Lovenox | 11 | $6,374 | $579 |
| Enoxaparin | 22 | $5,212 | $237 |
| Anastrozole | 86 | $2,091 | $24 |
| Prednisone | 100 | $1,657 | $17 |
| Megestrol Acetate | 23 | $1,225 | $53 |
| Clotrimazole | 20 | $1,188 | $59 |
| Tamoxifen Citrate | 14 | $987 | $70 |
| Dexamethasone | 22 | $910 | $41 |
| Bicalutamide | 41 | $797 | $19 |
| Morphine Sulfate Er | 26 | $490 | $19 |
| Levothyroxine | 17 | $463 | $27 |
| Gabapentin | 11 | $342 | $31 |
| Hydromorphone | 23 | $318 | $14 |
| Oxycodone-Acetaminophen | 13 | $262 | $20 |
| Lorazepam | 22 | $202 | $9 |
| Ondansetron | 19 | $169 | $9 |
2018: 27 drugs
| Ibrance | 39 | $479,966 | $12,307 |
| Cabometyx | 30 | $424,737 | $14,158 |
| Zytiga | 30 | $310,048 | $10,335 |
| Xtandi | 29 | $269,500 | $9,293 |
| Afinitor | 18 | $260,239 | $14,458 |
| Iressa | 17 | $136,310 | $8,018 |
| Votrient | 14 | $127,502 | $9,107 |
| Tarceva | 12 | $110,066 | $9,172 |
| Imatinib Mesylate | 42 | $16,017 | $381 |
| Enoxaparin | 16 | $7,325 | $458 |
| Exemestane | 11 | $3,570 | $325 |
| Anastrozole | 108 | $2,840 | $26 |
| Dexamethasone | 29 | $1,207 | $42 |
| Megestrol Acetate | 14 | $1,138 | $81 |
| Bicalutamide | 33 | $1,045 | $32 |
| Tamoxifen Citrate | 13 | $753 | $58 |
| Morphine Sulfate | 11 | $728 | $66 |
| Diphenoxylate-Atropine | 16 | $623 | $39 |
| Prednisone | 32 | $600 | $19 |
| Oxycodone | 13 | $580 | $45 |
| Lorazepam | 36 | $451 | $13 |
| Levothyroxine | 16 | $443 | $28 |
| Morphine Sulfate Er | 17 | $402 | $24 |
| Gabapentin | 14 | $389 | $28 |
| Ondansetron | 23 | $350 | $15 |
| Oxycodone-Acetaminophen | 16 | $346 | $22 |
| Hydrocodone-Acetaminophen | 11 | $155 | $14 |
2017: 20 drugs
| Xtandi | 41 | $391,325 | $9,545 |
| Cabometyx | 18 | $270,689 | $15,038 |
| Ibrance | 15 | $179,501 | $11,967 |
| Zytiga | 19 | $178,310 | $9,385 |
| Iressa | 16 | $122,778 | $7,674 |
| Tarceva | 12 | $102,560 | $8,547 |
| Imatinib Mesylate | 30 | $29,570 | $986 |
| Anastrozole | 130 | $3,747 | $29 |
| Exemestane | 11 | $3,547 | $322 |
| Tamoxifen Citrate | 24 | $1,491 | $62 |
| Megestrol Acetate | 21 | $1,487 | $71 |
| Bicalutamide | 27 | $1,209 | $45 |
| Diphenoxylate-Atropine | 19 | $843 | $44 |
| Ondansetron | 23 | $717 | $31 |
| Lorazepam | 33 | $507 | $15 |
| Prednisone | 14 | $378 | $27 |
| Gabapentin | 12 | $355 | $30 |
| Dexamethasone | 19 | $278 | $15 |
| Diphenhydramine | 18 | $244 | $14 |
| Alendronate | 11 | $156 | $14 |
2016: 20 drugs
| Zytiga | 41 | $358,797 | $8,751 |
| Tarceva | 34 | $261,482 | $7,691 |
| Gleevec | 33 | $144,050 | $4,365 |
| Votrient | 14 | $92,573 | $6,612 |
| Exemestane | 12 | $5,388 | $449 |
| Anastrozole | 145 | $4,896 | $34 |
| Tamoxifen Citrate | 37 | $2,298 | $62 |
| Megestrol Acetate | 23 | $1,719 | $75 |
| Clindamycin Phosphate | 18 | $1,465 | $81 |
| Bicalutamide | 26 | $1,332 | $51 |
| Hydrocortisone | 22 | $1,138 | $52 |
| Prednisone | 32 | $1,020 | $32 |
| Morphine Sulfate | 12 | $922 | $77 |
| Hydrocodone-Acetaminophen | 13 | $872 | $67 |
| Lorazepam | 52 | $779 | $15 |
| Nystatin | 20 | $777 | $39 |
| K-Tab Er | 16 | $562 | $35 |
| Diphenoxylate-Atropine | 17 | $477 | $28 |
| Hydromorphone | 15 | $448 | $30 |
| Alendronate | 17 | $254 | $15 |
2015: 25 drugs
| Gleevec | 21 | $220,157 | $10,484 |
| Zytiga | 24 | $194,116 | $8,088 |
| Tarceva | 14 | $98,243 | $7,017 |
| Lovenox | 24 | $14,495 | $604 |
| Exemestane | 12 | $8,009 | $667 |
| Anastrozole | 157 | $5,388 | $34 |
| Tamoxifen Citrate | 45 | $2,682 | $60 |
| Megestrol Acetate | 18 | $2,080 | $116 |
| Fentanyl | 14 | $1,826 | $130 |
| Oxycodone | 20 | $1,373 | $69 |
| Bicalutamide | 26 | $1,290 | $50 |
| Nystatin | 29 | $994 | $34 |
| Lorazepam | 62 | $987 | $16 |
| Morphine Sulfate Er | 16 | $976 | $61 |
| Doxycycline Monohydrate | 11 | $961 | $87 |
| Butalbital-Acetaminophen-Caffe | 11 | $830 | $75 |
| Hydromorphone | 21 | $774 | $37 |
| Hydrocodone-Acetaminophen | 17 | $754 | $44 |
| Prednisone | 29 | $747 | $26 |
| Hydrocortisone | 13 | $623 | $48 |
| K-Tab Er | 19 | $583 | $31 |
| Diphenoxylate-Atropine | 16 | $488 | $31 |
| Alendronate | 28 | $417 | $15 |
| Dexamethasone | 18 | $303 | $17 |
| Ondansetron | 14 | $266 | $19 |
2014: 24 drugs
| Gleevec | 32 | $329,439 | $10,295 |
| Tarceva | 40 | $249,555 | $6,239 |
| Zytiga | 23 | $149,168 | $6,486 |
| Lovenox | 34 | $27,995 | $823 |
| Anastrozole | 166 | $5,739 | $35 |
| Fentanyl | 26 | $4,107 | $158 |
| Oxycodone | 23 | $3,104 | $135 |
| Tamoxifen Citrate | 38 | $2,338 | $62 |
| Nystatin | 50 | $2,104 | $42 |
| Megestrol Acetate | 20 | $1,687 | $84 |
| Lorazepam | 87 | $1,375 | $16 |
| Morphine Sulfate Er | 17 | $1,250 | $74 |
| Bicalutamide | 23 | $1,030 | $45 |
| Hydrocodone-Acetaminophen | 31 | $918 | $30 |
| Oxycodone-Acetaminophen | 12 | $770 | $64 |
| Hydromorphone | 19 | $673 | $35 |
| Gabapentin | 12 | $624 | $52 |
| Diphenoxylate-Atropine | 23 | $582 | $25 |
| Prednisone | 26 | $365 | $14 |
| K-Tab Er | 21 | $314 | $15 |
| Alendronate | 21 | $313 | $15 |
| Ondansetron | 16 | $273 | $17 |
| Temazepam | 11 | $197 | $18 |
| Zolpidem | 12 | $84 | $7 |
2013: 19 drugs
| Tarceva | 44 | $255,202 | $5,800 |
| Gleevec | 27 | $230,808 | $8,548 |
| Afinitor | 13 | $139,144 | $10,703 |
| Zytiga | 16 | $96,091 | $6,006 |
| Lovenox | 22 | $19,779 | $899 |
| Anastrozole | 178 | $6,799 | $38 |
| Emend | 15 | $6,381 | $425 |
| Tamoxifen Citrate | 39 | $2,200 | $56 |
| Bicalutamide | 20 | $1,751 | $88 |
| Megestrol Acetate | 20 | $1,581 | $79 |
| Nystatin | 32 | $1,469 | $46 |
| Morphine Sulfate Er | 13 | $1,222 | $94 |
| Hydrocodone-Acetaminophen | 38 | $687 | $18 |
| Lorazepam | 40 | $681 | $17 |
| Ondansetron | 24 | $496 | $21 |
| Dexamethasone | 27 | $486 | $18 |
| Oxycodone-Acetaminophen | 14 | $379 | $27 |
| Prednisone | 17 | $203 | $12 |
| Zolpidem | 12 | $92 | $8 |
Money from drug and device companies
$125 in 2025
| 2025 | 1 | 1 | None | $125 |
| 2024 | 2 | 2 | None | $180 |
| 2023 | 6 | 8 | $5,660 | $6,314 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Exelixis | Cabometyx | $125 | 1 payment
|
See the published payment
| Exelixis | Meals · 2025-10-03 | Cabometyx | $125 |
See earlier years (2024, 2023)
2024: $180
| Aadi Bioscience | Fyarro | $105 | 1 payment
|
| Exelixis | Cabometyx | $75 | 1 payment
|
2023: $6,314
| Aadi Bioscience | Fyarro | $2,994 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $2,900 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $141 | 1 payment
|
| Exelixis | Cabometyx | $125 | 1 payment
|
| Astellas Pharma US | None | $118 | 1 payment
|
| Genentech USA | Tecentriq | $36 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · A Phase 1/2 Study of Oral Selpercatinib (Loxo-292) in Patients With Advanced Solid Tumors, Including Ret Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With Ret Activation (Libretto-001) · 2022 | Their institution | $24,469 |
| Eli Lilly and Company · A Phase 1/2 Study of Oral Selpercatinib (Loxo-292) in Patients With Advanced Solid Tumors Including Ret Fusion-Positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With Ret Activation (Libretto-001) · 2023 | Their institution | $10,920 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Mln9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma · 2020 | Their institution | $6,500 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1568549418
- Licence
- CA A64776California A64776: Current · expires 2028-04-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A647760
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-10-31
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 710 Lawrence Expy, Santa Clara, CA, 95051
This office lists an electronic records connection.